evipedia.ai
← Back

Calendula officinalis for Health & Longevity

Evidence Review created on 09/14/2026 using AI4L / Opus 5

Also known as: Calendula, Pot Marigold, Common Marigold, Scotch Marigold, English Marigold, Marybud

Motivation

Calendula officinalis (pot marigold) is a bright orange garden flower whose dried florets have been pressed into ointments, creams, tinctures and rinses for centuries. Its appeal rests on a narrow, concrete claim: placed on damaged skin or an inflamed mucous membrane, it calms redness and speeds repair. Concentrated flower extracts carry fat-soluble plant compounds that appear to blunt inflammation where they are applied.

The flower moved from kitchen gardens into European medical practice in the medieval period and was carried into battlefield wound care in the nineteenth and twentieth centuries. It is one of the few herbal preparations formally recognised by European regulators for minor skin inflammation, and one of a small number of botanicals that has been compared head to head with a standard hospital skin product in cancer care.

This review examines what the evidence shows about Calendula officinalis for wound repair, irritated skin and inflamed mucous membranes; how strong and how consistent that evidence is; what harms have been recorded; and how the preparations are dosed, sourced and monitored.

Benefits - Risks - Protocol - Conclusion

High-level sources that give substantial depth on Calendula officinalis, its chemistry, and the skin reactions it can provoke.

Only one of the six priority platforms, Life Extension, carries content on calendula: the other five cover metabolic, cognitive and cardiovascular subject matter, and both the web searches and the platform searches described above returned nothing relevant on this topical botanical. Rather than pad the list with marginal material, the remaining slots were left to a mechanism paper and a safety review instead of consumer skin-care blog posts, which repeat marketing claims without evidence.

Grokipedia

Calendula officinalis

The dedicated species entry, covering taxonomy, morphology, chemical composition, cultivation, history and uses, with a pharmacology section on active compounds, pharmacological effects, clinical research, and safety and toxicity.

Examine

Calendula Officinalis

Examine grades twelve calendula outcomes across ten conditions and 1,359 participants, assigning only C and D grades — the most compact independent appraisal of how thin the human evidence is.

ConsumerLab

No ConsumerLab article on Calendula officinalis exists. ConsumerLab tests ingestible supplements and does not review topical botanical ointments, creams or tinctures, which is how calendula is almost always used.

Systematic Reviews

Systematic reviews (structured searches and appraisals of all studies on a question) and meta-analyses (statistical pooling of results across trials) that bear on Calendula officinalis.

The principal trade-off here is efficacy against allergic skin sensitization. The efficacy side is well represented above. The harm side is not: no systematic review or meta-analysis is devoted to calendula safety alone, and adverse effects appear only as one component of the Natural Standard review. Cost is not a meaningful trade-off, since calendula preparations are inexpensive relative to every comparator they have been tested against.

Mechanism of Action

The flower head concentrates pentacyclic triterpenoid alcohols — chiefly faradiol monoesters — together with flavonoids such as quercetin and isorhamnetin, carotenoids, saponins and polysaccharides. Bioassay-guided fractionation showed the triterpenoids carry most of the topical anti-inflammatory activity, with free faradiol matching indomethacin, a standard anti-inflammatory drug, in an animal oedema model, and activity tracking faradiol monoester content across extracts. More recent work showed that C16-hydroxylated triterpenoids suppress release of interleukin 6, a signalling protein that drives inflammation. Downstream, extracts dampen nuclear factor kappa B (a master switch for inflammatory gene activity) and prostaglandin production, while promoting fibroblast migration, new blood vessel formation and granulation tissue (the new connective tissue and small vessels that fill a healing wound).

Two mechanistic readings compete. One holds that the triterpenoids are pharmacologically active in their own right. The other holds that much of the observed benefit in wound and radiation trials comes from the greasy vehicle — an occlusive ointment base keeps the wound bed moist and would speed repair with no active compound present. Trials comparing calendula against another emollient rather than nothing tend to be the negative ones, favouring the second reading.

Pharmacologically, calendula is a multi-component extract, not a single compound. Topical application produces negligible systemic absorption; faradiol esters stay in the outer skin layers and are hydrolysed locally. Orally, flavonoid glycosides are hydrolysed in the gut and conjugated in the liver. No human half-life, tissue distribution or cytochrome P450 (liver drug-metabolising enzyme) pathway is established for any constituent.

Historical Context & Evolution

Calendula officinalis was cultivated across medieval Europe as a pot herb and a wound remedy, and appears in the herbals of Culpeper and Gerard as a treatment for inflamed skin, ulcers and “hot swellings”. Its original use was therefore almost exactly its current one: a topical application for damaged or inflamed tissue. It also served as a culinary colouring and a cheap saffron substitute.

Two nineteenth-century developments carried it forward. Samuel Hahnemann adopted it as a homeopathic wound remedy, embedding calendula in a commercial supply chain that persists today. Independently, surgeons in the American Civil War and the First World War used calendula dressings on open wounds when antiseptics were scarce, generating a large body of uncontrolled clinical experience.

Its move toward health optimisation came from that wound-care record meeting modern phytochemistry. Once faradiol monoesters were identified as measurable anti-inflammatory markers in the 1990s, standardised extracts became possible, and German Commission E and later the European Medicines Agency’s herbal committee granted monograph status for inflammation of the skin, mouth and throat.

Scientific opinion has not settled. A large oncology trial in 2004, its ointment supplied by the homeopathy manufacturer Boiron, found calendula clearly superior to the reference topical agent; a larger trial in 2013 found no difference against plain aqueous cream. Neither result has been withdrawn. What changed was the comparator, not the plant: the earlier trial used an active product, the later a bland moisturiser. Pooled analyses now report no significant effect, while acute-wound trials continue to report benefit.

Expected Benefits

High 🟩 🟩 🟩

Faster Closure of Acute Skin Wounds

Topical Calendula officinalis extract shortens the time small acute wounds take to re-surface. The proposed mechanism is earlier resolution of the inflammatory phase with greater granulation tissue formation and faster epithelialization (regrowth of the surface skin layer across a wound). Evidence is two randomized controlled trials (studies that assign participants to treatment or comparison by chance) in acute hand and finger wounds and in perineal wounds after episiotomy, supported by consistent animal data in a systematic review. Both trials were small and single-centre.

Magnitude: Mean epithelialization took 8.6 ± 4.7 days with standardised extract versus 13.2 ± 7.4 days with mineral oil, and healing speed was 9.5%/day versus 6.2%/day (p < 0.05; p is the probability the difference arose by chance, and values under 0.05 are conventionally treated as unlikely to be chance); the episiotomy trial reported less redness and swelling throughout follow-up.

Medium 🟩 🟩

Reduced Pain at Damaged or Irradiated Skin Sites ⚠️ Conflicted

Applied to a wound, an episiotomy repair or an irradiation field, calendula preparations lower reported pain, presumably by suppressing prostaglandin-driven pain signalling under a moist, occluded surface. The episiotomy trial and the phase III breast-irradiation trial, its ointment supplied by Boiron, a homeopathy manufacturer, both found less pain; the larger blinded trial against aqueous cream found none. Neither positive trial was placebo-controlled or blinded to the person applying the product. Net reading: pain relief holds for fresh surgical wounds but not for irradiated skin against a plain moisturiser.

Magnitude: Direction is consistent under one condition — a fresh surgical wound: pain scores fell significantly from day two after episiotomy, and radiation-induced pain fell significantly against trolamine but not against aqueous cream. The trials report significance levels rather than a common effect size, and no meta-analysis of calendula and pain exists.

Resolution of Vaginal Candidiasis and Bacterial Vaginosis

A 1% calendula vaginal cream cleared vaginal yeast infection and bacterial vaginosis (an overgrowth of vaginal bacteria diagnosed by the Amsel criteria — discharge, raised pH, fishy odour and clue cells) about as well as standard drug therapy, though more slowly. Mechanism is presumed direct antimicrobial and anti-inflammatory action on the vaginal mucosa. Evidence is two active-comparator randomized trials, versus clotrimazole and versus metronidazole, both single-centre, neither placebo-controlled, and both conducted in the same regional research setting.

Magnitude: Negative testing for candidiasis was 49% versus 74% with clotrimazole at 10–15 days (odds ratio 0.32, 95% confidence interval 0.16–0.67; odds ratio means how much more or less likely an outcome is in one group than the other, with 1.0 meaning no difference, and confidence interval means the range in which the true value most likely lies) but 77% versus 34% at 30–35 days (odds ratio 3.1, 95% confidence interval 1.5–6.2).

Reduced Dental Plaque and Gingival Inflammation

A diluted calendula tincture used as a twice-daily mouthrinse lowered plaque and gum inflammation scores. Mechanism combines antibacterial activity against plaque organisms with local suppression of gingival inflammation. Evidence is one 240-participant six-month randomized trial of calendula tincture against a water rinse and one placebo-controlled trial of a three-herb mouthwash containing calendula that matched chlorhexidine. The second cannot attribute effect to calendula alone, and the first used an inactive water comparator.

Magnitude: Direction is consistent under defined conditions — plaque, gingival and sulcus-bleeding index scores fell significantly against the comparator rinse at three and six months, with the largest reduction when rinsing followed professional scaling. The published trials report significance levels rather than a pooled between-group index difference.

Faster Recovery of Irritated Skin

On skin inflamed by irritants, calendula-containing preparations restore barrier function and reduce visible dermatitis. The mechanism is local anti-inflammatory action plus improved water retention in the outer skin layer. Evidence is a randomized split-forearm trial of 1% supercritical extract in an emollient and randomized trials in infant irritant dermatitis against aloe and against olive oil. Comparators were active, sample sizes small, and a further trial found bentonite clay superior to calendula.

Magnitude: Skin hydration was significantly greater than untreated control (p = 0.017) and than the emollient base alone (p = 0.035) on day 4, persisting to day 8 (p = 0.043), with lower transepidermal water loss (how fast water evaporates through the skin, a measure of barrier integrity) than control on day 3 (p = 0.022).

Low 🟩

Prevention of Acute Radiation Dermatitis ⚠️ Conflicted

Prophylactic ointment during radiotherapy: a phase III trial against trolamine found a large benefit; a blinded trial against aqueous cream found none, and pooling shows no effect. Boiron, a homeopathy manufacturer, supplied the positive trial’s ointment. Net reading: benefit appears only against an active comparator, not against plain moisturising.

Magnitude: Moderate-or-worse dermatitis occurred in 41% versus 63% with trolamine in the positive trial, but 23% versus 19% against aqueous cream in the larger blinded trial, and pooled estimates show no significant reduction.

Healing of Chronic Leg and Foot Ulcers ⚠️ Conflicted

On venous leg and diabetic foot ulcers, calendula reduced ulcer area in some controlled studies and not in others, as catalogued in the wound systematic review; a small four-arm study helped only alongside laser therapy. Net reading: chronic-wound benefit is unproven and depends on ulcer type.

Magnitude: Two controlled venous-ulcer studies reported decreased ulcer surface area versus control, while a diabetic leg-ulcer randomized trial reported none; the literature gives no pooled effect size across ulcer types.

Reduced Severity of Cancer-Therapy Mouth Ulceration

Calendula mouthrinses have been tested for mucositis (painful ulceration of the mouth lining) during radiotherapy and chemotherapy. A systematic review of medicinal plants placed calendula among agents that improved lesions, but with chamomile far better supported, and a phase III trial of a multi-herb rinse was negative.

Magnitude: Not quantified in available studies. The individual trials are small, use different concentrations and multi-herb formulations, and report ulceration grades without a common scale, so no pooled or representative figure exists.

Reduced Inflammatory Acne Lesions

A facial serum containing calendula alongside snail secretion filtrate and licorice root extract reduced inflammatory acne lesions under face masks in a randomized placebo-controlled trial. Calendula’s contribution cannot be separated from the other two actives, so the finding supports the formulation, not the plant.

Magnitude: Inflammatory lesion count fell by 33.9% more than placebo (95% confidence interval 2.5% to 65.2%; p = 0.03), with no significant change in non-inflammatory lesions or skin biophysical measures.

Reduced Ear Pain in Acute Middle-Ear Infection

Herbal ear drops combining calendula with garlic, mullein and St John’s wort eased ear pain in two randomized trials in children, against anaesthetic drops and with or without an antibiotic. Calendula’s own contribution cannot be separated from the other three plants, and most of the pain resolved spontaneously.

Magnitude: Direction is consistent under one condition — drops used without a concurrent antibiotic — with pain scores falling over three days at least as fast as with anaesthetic drops; the trials report significance levels rather than a between-group effect size.

Speculative 🟨

Body-Wide Anti-Inflammatory Effect from Oral Use

Cell and animal work shows suppressed interleukin 6 release and reduced inflammatory tissue damage. No human trial has measured a body-wide inflammatory marker after oral calendula, so the basis is mechanistic only.

Antitumour and Antimetastatic Activity

Extracts kill cancer cell lines and reduce tumour spread in animals, per a review of calendula in oncology. No human trial has tested it as anticancer treatment; the basis is preclinical only.

Systemic Antioxidant and Genome-Protective Effects

Feeding studies in pigs and quail report improved antioxidant markers and reduced genetic damage. These are unvalidated biomarkers in animals with no human outcome data, so the basis is preclinical only.

Benefit-Modifying Factors

  • Daisy-family allergy status: Prior sensitization to Asteraceae plants converts a benefit into a harm. No pharmacogenetic variant predicts calendula response; human leukocyte antigen genes (which shape immune recognition) influence sensitization risk but are not clinically tested for this purpose.

  • Baseline wound and inflammation severity: Benefit scales with how much repair is needed. Trials in shallow acute wounds and mild gum inflammation show clear gains; those in near-healed or minimally inflamed skin show none, which partly explains the negative radiation trials.

  • Baseline barrier and mucosal markers: Higher pre-treatment transepidermal water loss, raised vaginal pH above 4.5, and higher plaque index scores each mark more room for measurable improvement. Near-normal baselines leave little detectable signal.

  • Sex-based differences: Almost all clinical evidence comes from women — breast irradiation, episiotomy, vaginal infection. Men appear only in the hand-wound, ulcer and gum trials. No sex difference in topical response has been demonstrated, but male data are sparse.

  • Pre-existing conditions: Diabetes, peripheral arterial disease, venous insufficiency and immunosuppression all slow wound repair and blunted calendula’s effect in chronic-ulcer studies. Active bacterial infection requires antimicrobial treatment; calendula does not substitute for it.

  • Age-related considerations: Older skin is thinner, less vascular and slower to re-epithelialize, so absolute healing times lengthen even where relative benefit holds. Adults over 70 are barely represented in any calendula trial.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High. The randomized trials report adverse events only as absent or unclassified rather than as measured outcomes, and no controlled trial has documented a reproducible harm; the entire harm literature consists of case reports, patch-test clinic series and animal toxicology.

Medium 🟥 🟥

Allergic Contact Dermatitis

Calendula belongs to the daisy family, whose sesquiterpene lactones (plant chemicals that commonly trigger skin allergy) are an important cause of allergic plant contact dermatitis in Europe. Repeated application to broken skin is the highest-risk exposure. Evidence is consistent patch-test clinic data across the family plus case reports naming calendula specifically, reviewed in Compositae sensitization. Reactions are delayed, itchy and eczematous and clear once the product is withdrawn, but the underlying sensitization is permanent.

Magnitude: Direction is established but calendula-specific incidence is not: epidemiological sensitization data exist only for arnica and German chamomile within the family, and calendula’s own evidence is anecdotal. The literature reports no incidence figure for calendula.

Slower Early Clearance of Vaginal Infection Than Standard Drug Therapy

Choosing calendula over an antifungal delays symptom and laboratory clearance in the first two weeks, exposing the user to a longer symptomatic period and, in principle, to ascending infection. Evidence is the triple-blind trial against clotrimazole, in which calendula was significantly worse at the first assessment before overtaking at the second. Severity is low and the deficit is reversible by switching agents.

Magnitude: Negative testing at 10–15 days was 49% with calendula versus 74% with clotrimazole (odds ratio 0.32, 95% confidence interval 0.16–0.67), an absolute deficit of 25 percentage points at the two-week mark.

Low 🟥

Poor Cosmetic Acceptability and Application Difficulty

Calendula ointments are thick, greasy and staining, and were rated significantly harder to apply than the comparator in the phase III irradiation trial, which matters because incomplete application removes any benefit. Evidence is uncontrolled patient-reported experience within one trial.

Magnitude: Application was rated difficult by 30% of patients using calendula versus 5% of those using trolamine, while self-assessed overall satisfaction was nonetheless higher in the calendula group.

Product Variability and Contamination in Unregulated Preparations

Extraction method drives composition, so two products labelled identically can differ several-fold in active content, and safety data on one extract do not transfer to another — the core conclusion of the Cosmetic Ingredient Review assessment, which judged the available data insufficient. Herbal-extract sellers have received manufacturing-violation warnings.

Magnitude: Anti-inflammatory activity is proportional to faradiol monoester content, which varies with extraction, so potency differences across marketed products are expected; no survey has quantified the spread in retail products.

Masking or Delaying Treatment of a Serious Wound

Self-treating an infected, ischaemic or non-healing ulcer with a botanical ointment defers diagnosis. The wound systematic review found no benefit in burns or diabetic leg ulcers, precisely the wounds where delay causes harm. Evidence is indirect, inferred from absent efficacy rather than from recorded events.

Magnitude: Not quantified in available studies. No trial has measured delayed presentation or wound deterioration as an endpoint, so only the absence of efficacy in these wound types is documented.

Speculative 🟨

Liver Enzyme Changes with Prolonged High-Dose Oral Extract

Rats given oral extract for 90 days showed altered liver enzymes and slight hepatic changes at high doses. No human oral-toxicity data exist; the basis is animal work only.

Uterine Stimulation and Pregnancy Risk

Traditional use as a menstruation-inducing agent and animal reports of uterine activity underpin the standard warning against oral use in pregnancy. No controlled human data exist; the basis is traditional report and animal work.

Additive Sedation and Blood-Pressure Lowering

Animal studies report sedative and hypotensive effects of oral extract. No human trial has measured either, and no interaction case report exists, so the basis is mechanistic and preclinical only.

Risk-Modifying Factors

  • Immune-recognition genetics: Human leukocyte antigen variants, which govern how the immune system presents foreign molecules, shape susceptibility to sesquiterpene lactone sensitization. No test is used clinically to predict it, and no drug-metabolising variant is relevant to topical use.

  • Baseline sensitization markers: A prior positive patch test to the Compositae mix or sesquiterpene lactone mix identifies people who will react. For oral preparations, baseline liver enzymes give a reference point given the animal hepatic signal.

  • Sex-based differences: Sensitization to daisy-family cosmetics is reported more often in women, largely reflecting far greater exposure to botanical skin-care products rather than a demonstrated biological difference in susceptibility.

  • Pre-existing conditions: Atopic dermatitis and chronic venous leg ulcers both raise sensitization risk sharply, because a defective barrier and prolonged occluded application together maximise allergen presentation. Pregnancy contraindicates oral use.

  • Age-related considerations: Older adults with stasis dermatitis (itchy, scaling skin over swollen lower legs) carry the highest sensitization risk from months of topical application to a leg ulcer. Thinner aged skin also increases absorption.

Key Interactions & Contraindications

  • Sedative and hypnotic medications: Caution with oral calendula alongside benzodiazepines (diazepam, lorazepam) or barbiturates (phenobarbital); animal sedative activity raises a theoretical risk of additive drowsiness. Separate dosing or avoid oral use; topical use carries no such concern.

  • Antihypertensive medications: Caution with oral calendula alongside blood-pressure-lowering drugs (amlodipine, lisinopril, losartan); animal data show hypotensive activity, so additive lowering and light-headedness are theoretically possible. Monitor blood pressure if oral use begins.

  • Glucose-lowering medications: Caution with oral calendula alongside antidiabetic agents (metformin, glipizide, empagliflozin); animal antidiabetic activity makes additive hypoglycaemia (blood sugar falling too low, causing shakiness and confusion) theoretically possible. Monitor capillary glucose during the first two weeks of oral use.

  • Topical corticosteroids and other topical anti-inflammatories: Monitor when co-applied (hydrocortisone, betamethasone, diclofenac gel). No pharmacological conflict is documented, but stacking products on one field confuses attribution of any skin reaction. Apply at separate times.

  • Over-the-counter sedating antihistamines: Caution with diphenhydramine, doxylamine and chlorphenamine taken with oral calendula, for the same theoretical additive drowsiness. Consequence is impaired alertness rather than a defined toxicity; avoid combining before driving.

  • Over-the-counter topical antiseptics and keratolytics: Caution with povidone-iodine, hydrogen peroxide, benzoyl peroxide and salicylic acid on the same site. Oxidising and exfoliating agents strip the barrier and raise irritant and sensitization risk. Separate by at least several hours.

  • Sedating supplements: Caution with valerian, kava, passionflower and melatonin taken with oral calendula; additive drowsiness is theoretically possible on the same animal evidence. No case report exists. Reduce or avoid concurrent oral use.

  • Other daisy-family botanicals: Caution with chamomile, echinacea, arnica, feverfew, milk thistle and yarrow, whether topical or oral. Cross-reactivity within the family means one sensitization can produce dermatitis on exposure to any of them.

  • Supplements with additive effects: Monitor blood-glucose-lowering supplements (berberine, chromium, cinnamon extract) and blood-pressure-lowering supplements (beetroot nitrate, magnesium) with oral calendula; sharing its theoretical directions of effect, they could compound low blood sugar or light-headedness. Combination need not be avoided.

  • Radiotherapy: Monitor timing. A thick ointment layer left on the skin during irradiation can add surface dose, worsening the reaction it was meant to prevent. Apply after each session and remove before the next.

  • Other interventions: Monitor when calendula is added to laser therapy, compression bandaging or occlusive dressings for ulcers. Benefit in the ulcer literature appeared only in combination with such treatments, and occlusion increases sensitization risk.

Populations who should avoid Calendula officinalis:

  • Anyone with known Asteraceae or Compositae allergy, including a positive patch test to the Compositae mix or the sesquiterpene lactone mix — absolute contraindication for topical and oral use.

  • Pregnant women, for oral preparations at any trimester, given traditional menstruation-inducing use and animal uterine activity; topical use on intact skin is not restricted.

  • Breastfeeding women, for oral preparations, on absence of lactation safety data rather than on recorded harm.

  • Anyone with a deep, penetrating, bite, burn or surgically closed wound, or a diabetic foot ulcer graded Wagner 2 or above, where calendula displaces required wound care.

  • Anyone scheduled for general anaesthesia within 14 days, for oral preparations, given the theoretical additive sedative effect.

  • Infants under 1 month of age, for any preparation, on absence of data in that group.

Risk Mitigation Strategies

  • 48-hour forearm patch test before first broad use: A coin-sized amount on the inner forearm, inspected at 48 and 72 hours, surfaces allergic contact dermatitis before it is discovered across a whole irradiation field or leg ulcer.

  • Continuous application on chronic wounds capped at 4–6 weeks: Reassessment at each interval, rather than indefinite use, limits the prolonged occluded exposure to broken skin that is the single largest driver of daisy-family sensitization.

  • Discontinuation at the first increase in itch or spreading redness: New eczematous change after 48–72 hours of use signals allergic contact dermatitis, not the underlying condition worsening; continuing past that point entrenches lifelong sensitization.

  • Application after each radiotherapy session, never within 4 hours before: Wiping the field clean before treatment prevents a thick ointment layer from adding surface radiation dose and worsening the skin reaction.

  • Antimicrobials retained as first-line for diagnosed infection: Reassessment of any vaginal or wound infection at 7 days, with a switch if it is not clearing, prevents the two-week clearance deficit against standard antifungal treatment from becoming a prolonged infection.

  • Oral use confined to short courses and excluded in pregnancy: Infusions of 1–2 g dried florets up to three times daily for under 4 weeks address the animal hepatic signal and the traditional uterine-stimulation concern.

  • Extracts standardised to faradiol monoester or a stated extract percentage: A 2–10% ointment or 1–2% cream from manufacturers publishing batch testing avoids the several-fold potency variation and contamination seen in unregulated preparations.

  • Daisy-family botanicals not stacked: Keeping calendula off skin also treated with chamomile, arnica or echinacea preparations prevents cross-reactive sensitization and keeps the source of any reaction identifiable.

Therapeutic Protocol

  • Standard topical preparation: 2–10% flower extract in an ointment base, or a 1–2% cream, applied to clean skin two to three times daily until the wound or dermatitis resolves. This is the regimen used across the wound-healing literature.

  • Radiotherapy field protocol: Ointment applied to the irradiated field after every session and again at night, from the first fraction to two weeks after the last, following the Centre Léon Bérard phase III protocol.

  • Vaginal preparation: 5 g of 1% vaginal cream inserted by applicator each night for seven consecutive nights, the regimen used in both the candidiasis and bacterial vaginosis trials and listed by Examine.

  • Oral and mucosal rinse: 2 mL tincture diluted in 6 mL water, rinsed twice daily; or 1–2 g dried florets infused in 150 mL hot water, gargled two to three times daily.

  • Competing approaches — conventional: Standard dermatology and oncology practice uses aqueous cream, glycerine-based emollients, trolamine or silicone film dressings, all of which have their own trial evidence and none of which is framed here as the default choice.

  • Competing approaches — integrative: Anthroposophic and homeopathic practice uses Weleda calendula ointment and Boiron’s Pommade au Calendula. Both firms sell the products their affiliated practitioners recommend, and Boiron supplied the ointment for the positive irradiation trial.

  • Best time of day: No circadian pattern is established. Practical timing is set by the treatment schedule: after radiotherapy sessions, after washing, at bedtime for vaginal cream, and after brushing for a mouthrinse.

  • Half-life in the body: No human half-life exists for any calendula constituent. Topical faradiol esters stay in the outer skin layers and clear with normal skin turnover, so dosing is set by reapplication frequency, not by interval.

  • Single versus split dosing: Split. Every effective protocol reapplies two to three times daily, because local residence time rather than a systemic concentration determines exposure. Single daily application has not been tested against multiple.

  • Genetic polymorphisms: No variant guides dose selection. Drug-metabolising variants such as CYP3A4 or CYP2C9 are irrelevant to topical use, and immune-recognition genes affect allergy risk rather than the effective dose.

  • Sex-based differences: No sex-adjusted dosing exists. Regimens were established in predominantly female populations and are applied unchanged to men, without evidence that response differs.

  • Age-related considerations: Older adults with thin or fragile skin are usually started at the lower end, a 1–2% cream rather than a 10% ointment, and reassessed at two weeks, since aged skin absorbs more and repairs more slowly.

  • Baseline biomarker levels: Wound surface area, dermatitis grade, vaginal pH and plaque index set the starting point and determine whether any change is measurable; near-normal baselines make the protocol unproductive.

  • Pre-existing health conditions: Diabetes, arterial insufficiency and venous stasis all call for the underlying condition to be treated first, with calendula as an addition to compression, offloading or laser therapy rather than a replacement.

Discontinuation & Cycling

  • Course length: Short-term and episodic, never lifelong. Topical courses run until the wound or dermatitis resolves, typically 1–4 weeks; the radiotherapy protocol ends two weeks after the final fraction; vaginal courses are fixed at seven nights.

  • Withdrawal effects: None recorded. No trial has reported rebound inflammation, delayed healing or any symptom on stopping, and no physiological dependence mechanism is plausible for a topical botanical.

  • Tapering: Not applicable. Preparations are stopped abruptly at the end of a course, and no tapering schedule appears in any protocol or monograph.

  • Cycling: Not required to maintain efficacy, since no tolerance has been demonstrated. Breaks are worth taking for a different reason — cumulative occluded exposure is what drives daisy-family skin sensitization.

Sourcing and Quality

  • Plant part and species: Quality material is Calendula officinalis flower heads only. Whole-herb material dilutes the active fraction, and ornamental Tagetes species sold as “marigold” are a different genus with different chemistry.

  • Standardisation marker: Better-characterised products state an extract percentage (2–10% ointment, 1–2% cream) or a declared faradiol monoester content, the marker shown to track anti-inflammatory activity across extracts.

  • Extraction method: Supercritical carbon dioxide extracts concentrate the triterpenoids; hydroalcoholic tinctures favour flavonoids; oil macerates are weakest. Method determines potency, so products are not interchangeable at equal labelled percentage.

  • Third-party testing: For ingestible preparations, the meaningful signals are United States Pharmacopeia or NSF certification and batch certificates covering pesticide residues, heavy metals and microbial limits.

  • Reputable suppliers: Weleda and Boiron dominate the standardised topical market and supplied the products used in the major trials. Compounding pharmacies can prepare calendula ointments to a specified extract percentage on prescription.

  • Formulation base matters: An occlusive ointment base contributes to wound outcomes independently of the plant, so a well-formulated base is part of the product, not a neutral carrier — a point that also explains several negative trials.

Practical Considerations

  • Time to effect: Fast for local endpoints. Wound and dermatitis trials detect differences within 3–8 days, gum-inflammation trials at three months, and vaginal courses are judged at 7–14 days. No effect accumulates over months.

  • Common pitfall — wrong plant: Buying Tagetes “marigold” products instead of Calendula officinalis. The two are unrelated genera, and Tagetes carries its own photosensitising thiophenes rather than the triterpenoids that drive calendula’s activity.

  • Common pitfall — expecting systemic effects: Drinking calendula tea for body-wide inflammation. All positive human evidence is topical or mucosal; no human trial has shown a systemic effect from any oral preparation.

  • Common pitfall — inconsistent application: Applying once daily or skipping days. Every effective protocol reapplies two to three times daily, and the trials that measured adherence found incomplete application in a substantial minority.

  • Regulatory status: Not an approved drug in the United States; it is a cosmetic ingredient and a homeopathic over-the-counter category. The European Medicines Agency grants it traditional-use herbal monograph status for minor skin inflammation.

  • Cost and accessibility: Neither expensive nor hard to obtain. Standardised ointments cost single-digit sums per tube and are sold without prescription in pharmacies and supermarkets across Europe and North America.

  • Structural cost incentives: Insurers and hospital pharmacies have a financial reason to prefer a cheap botanical over branded silicone dressings or trolamine, while those manufacturers fund most comparative trials — a bias running in both directions here.

Interaction with Foundational Habits

  • Sleep: Direct interaction is absent for topical use, which produces negligible systemic exposure. For oral preparations the direction would be sedating if the animal data translate, but no human study has measured sleep architecture or latency, so no timing recommendation is supportable. Practically, night-time application suits greasy ointments because staining matters less.

  • Nutrition: No interaction in either direction. Calendula depletes no nutrient, requires no particular diet, and its carotenoid content is nutritionally trivial at the doses used. Culinary use of the florets as a colouring agent delivers amounts far below any tested therapeutic dose, so it neither adds to nor subtracts from a protocol.

  • Exercise: Indirect and minor. There is no evidence of blunted muscle hypertrophy or interference with training adaptation, since the compounds do not reach muscle in meaningful concentration. The practical point runs the other way: friction abrasions, blisters and chafing are exactly the shallow acute wounds where topical benefit is best supported.

  • Stress management: No direct interaction. No human study has measured cortisol, heart-rate variability or any stress marker after calendula in any form. The animal sedative signal that underlies the theoretical drug interactions has never been reproduced in people, so claims of a calming effect remain untested.

Monitoring Protocol & Defining Success

Before starting, record the specific thing the preparation is meant to change. For a wound, photograph it against a scale and measure its surface area; for a skin reaction, record the dermatitis grade; for a vaginal course, measure pH and confirm the diagnosis by microscopy; for a mouthrinse, have plaque and gingival indices scored. In atopic dermatitis, a history of plant contact allergy, or a chronic leg ulcer, protocols add a patch test to the Compositae mix before extended use. For oral preparations only, check liver enzymes at baseline. Ongoing monitoring is deliberately short: reassess the primary measurement at 1 week and 4 weeks for wounds and dermatitis, at 7 and 30 days for a vaginal course, at 3 and 6 months for gum indices, and inspect the application site at 48–72 hours for any new eczematous reaction.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Wound surface area (planimetry) Steady decline; near-complete closure of shallow acute wounds by 8–10 days Objective proof of the main claimed benefit Photograph with a ruler in frame under identical lighting; planimetry means measuring area from a calibrated photograph
Radiation skin toxicity grade Grade 0–1 throughout treatment Detects whether the protocol is preventing moderate-or-worse injury Graded on the Radiation Therapy Oncology Group scale, a 0–4 clinician-scored measure of irradiated-skin damage; assessed weekly during a course
Transepidermal water loss Return to within 10% of the untreated adjacent-site value Tracks skin barrier recovery independently of how the skin looks Transepidermal water loss is how fast water evaporates through the skin; measure in a stable room at rest, not after showering or exercise
Vaginal pH 3.8–4.5 Confirms the vaginal environment has actually normalised, not just that symptoms eased Conventional laboratories flag only above 4.5; test away from menses and at least 24 hours after intercourse
Nugent score 0–3 Distinguishes genuine microbiological cure from symptom relief The Nugent score is a 0–10 microscope-based grade of vaginal bacterial balance; pair with the Amsel criteria for diagnosis
Gingival Index and Plaque Index Gingival Index below 1.0; Plaque Index below 1.0 Quantifies gum inflammation and plaque rather than relying on bleeding impressions Both are 0–3 clinician-scored dental scales; score before the daily rinse and at the same appointment time
High-sensitivity C-reactive protein Below 1.0 mg/L The only practical check on whether an oral preparation does anything body-wide High-sensitivity C-reactive protein is a blood marker of body-wide inflammation; conventional cut-off is below 3.0 mg/L; fast 8 hours and avoid testing within 2 weeks of any infection
Alanine and aspartate aminotransferase Both below 25 U/L Screens the animal hepatic signal in anyone using oral preparations These are liver enzymes; conventional upper limits run to 40–45 U/L, well above the functional target; fasting sample, avoid after heavy exercise or alcohol
Compositae mix patch test Negative at 48 and 96 hours Identifies daisy-family allergy before prolonged application Performed by a dermatology service alongside the sesquiterpene lactone mix; no established target other than negative

Qualitative markers worth tracking alongside the measurements:

  • Pain at the treated site, scored 0–10 daily and expected to fall within the first two to three days.

  • Itch or burning that appears or worsens after 48 hours, which points to allergy rather than to the original problem.

  • Ease of application and staining, since a product that is unpleasant to use is applied incompletely.

  • Sleep quality and daytime alertness for anyone using oral preparations, given the untested sedation signal.

  • Overall comfort and confidence in the treated area, which is what most users judge success by regardless of the measurements.

Emerging Research

  • No large monotherapy trial is running: The ClinicalTrials.gov registry holds 25 studies naming calendula, nearly all of multi-ingredient products. The absence of a funded, adequately powered trial of standardised calendula alone is the field’s central limitation.

  • Completed comparator trial defining current uncertainty: NCT01688479, a phase III trial of 420 breast cancer patients at Karolinska comparing calendula cream with aqueous cream, found no difference and is the strongest evidence against the radiation indication.

  • Hand-foot syndrome prevention: NCT04833998, a phase II trial of 54 patients testing a thoitaine, aloe and calendula moisturiser against capecitabine-induced hand-foot syndrome. Status is unconfirmed since 2021; a positive result would extend calendula into chemotherapy skin toxicity.

  • Diabetic foot ulcer combination: NCT03166423, a phase I/II trial of 90 patients testing snail slime with natural extracts including calendula for ulcer healing. Status unconfirmed; it addresses the wound type where calendula has repeatedly failed.

  • Engineered production of the active compounds: Golubova et al., 2025 reconstructed the triterpenoid pathway in a plant chassis. Purified faradiol at defined dose would finally allow a placebo-controlled test of the compound rather than of an extract.

  • Research that could strengthen the case: A trial of standardised extract against an identical vehicle base in acute wounds would separate the plant from the ointment, the confound flagged by Givol et al., 2019 and unresolved in every existing study.

  • Research that could weaken the case: Further pooling of radiation trials is likely to reinforce the null found by Robijns et al., 2023, and a formal sensitization survey could put a real incidence figure on the allergy risk that is currently only anecdotal.

Conclusion

Calendula officinalis is a garden flower whose fat-soluble compounds calm inflammation in the tissue they touch. That is the whole of its plausible reach: the evidence for benefit is local, and nothing in it supports a body-wide or life-extending effect.

Where the evidence is strongest, it is genuinely useful. Shallow acute wounds close faster and hurt less under a calendula ointment, and the same holds for the surgical cut made during childbirth. Vaginal infection, gum inflammation and irritated skin all show benefit of a lesser but real kind, usually against another real treatment rather than a placebo. The much-publicised use during radiation treatment is the weakest link in the chain, not the strongest: it beat one active product in a single trial and matched a plain moisturiser in a larger one, and combining them leaves nothing.

Two things temper confidence. Most trials are small, run at one hospital, and the person applying the product knew which one it was; the strongest positive result used an ointment supplied by a homeopathy manufacturer that sells it. Comparisons against branded barrier products carry their own commercial pull, since those makers fund most trials. On the other side, the greasy base itself heals wounds, so part of what looks like plant activity may be the base.

Harm is modest and predictable. The one recurring problem is daisy-family skin allergy, which is permanent once acquired and most likely after long application to broken skin. Everything else rests on animal work.

Top - Benefits - Risks - Protocol